Mental Health Clinics in Hamlet, NC Accepting Medicare
16 Mental Health Clinics found. Showing 1 - 16
 Ziel Counseling Group Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 766 Mill Rd, Hamlet, NC 28345 Phone: 910-536-0463 |
Monarch Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 841 Circlewood Dr, Hamlet, NC 28345 Phone: 910-557-5337 |
Overflow Counseling And Consulting Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 509 W Hamlet Ave, Hamlet, NC 28345 Phone: 910-206-5747 |
Clearwaters Counseling Services, Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 34 W Main St, Hamlet, NC 28345 Phone: 704-475-6442 |
Monarch Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 113 Charlotte St, Hamlet, NC 28345 Phone: 910-582-3780 |
Sandhills Alternative Academy, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 121 Pine Needle Ln, Hamlet, NC 28345 Phone: 910-417-4922 |
Sandhills Behavioral Health Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1000 W Hamlet Ave, Hamlet, NC 28345 Phone: 910-205-8000 Fax: 910-246-0669 |
Ats Of North Carolina, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 815 W Hamlet Ave, Hamlet, NC 28345 Phone: 760-710-0968 |
Monarch Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 968 Wiregrass Rd, Hamlet, NC 28345 Phone: 910-582-9913 |
Goodwin Psychological Services Psychologist Medicare: Medicare Enrolled Practice Location: 34 W Main St, Suite D, Hamlet, NC 28345 Phone: 910-557-0044 Fax: 910-716-9177 |
Clearwaters Counseling Services, Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 34 W Main St, Hamlet, NC 28345 Phone: 170-447-5644 Fax: 910-448-9008 |
Trinity Family Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 39 W Main St, Hamlet, NC 28345 Phone: 910-205-3080 |
L&m Healthcare Services,llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 2 W Main St, Suite 212, Hamlet, NC 28345 Phone: 910-410-8900 |
Teaching And Training Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 440 Battley Dairy Rd, Hamlet, NC 28345 Phone: 910-461-9186 Fax: 910-461-3236 |
Talk To Us Support Services Incorpo Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 208 Piney Pointe Dr, Hamlet, NC 28345 Phone: 910-682-4186 |
United Mental Health Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 204 Quail Hollow Dr, Hamlet, NC 28345 Phone: 910-318-6771 |
News Archive
ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.
EpiCept announces opinion by European Regulatory Authority on Ceplene
EpiCept Corporation has announced that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued, as expected following the trend vote announced last month, a negative opinion regarding the marketing authorization application (MAA) for Ceplene (histamine dihydrochloride) for the remission maintenance and prevention of relapse of patients with Acute Myeloid Leukemia (AML) in first remission.
CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer
Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.
New strategy to hinder emergence of antimicrobial-resistant pathogens
With many disease-causing bacteria ratcheting up their shields against current drugs, new tactics are vital to protect people from treatment-resistant infections.
› Verified 8 days ago